SCHEMBL17843403

SCHEMBL17843403

CCc1ccc(N(CC(C)C)S(=O)(=O)c2ccc(OC)cc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RORC P51449 10/20 0.63
CNR2 P34972 3/20 0.55
CNR1 P21554 2/20 0.55
IL17A Q16552 3/20 0.54
KEAP1 Q14145 1/20 0.54
NFE2L2 Q16236 1/20 0.54
ALDH1A1 P00352 2/20 0.52
NR3C1 P04150 1/20 0.52
PGR P06401 1/20 0.52
LMNA P02545 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
NR1H2 P55055 1/20 0.50
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
TSHR P16473 1/20 0.49
CYP2C19 P33261 1/20 0.49
MCL1 Q07820 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5623334 0.92 KEAP1 (0.62) RORCCNR2CNR1KEAP1NFE2L2
SCHEMBL17843295 0.84 MCL1 (0.58) RORCCNR2CNR1IL17ATSHR
SCHEMBL20280650 0.82 RORC (0.63) RORCIL17AALDH1A1TSHRMCL1
SCHEMBL17843349 0.81 RORC (0.55) RORCIL17A
SCHEMBL20280220 0.81 RORC (0.55) RORCIL17AMCL1
SCHEMBL15353046 0.81 RORC (0.55) RORCIL17AMCL1
SCHEMBL9277823 0.80 KEAP1 (0.59) CNR2CNR1KEAP1NFE2L2ALDH1A1
SCHEMBL9277825 0.79 KEAP1 (0.52) KEAP1NFE2L2ALDH1A1LMNANPSR1
SCHEMBL5622498 0.78 KEAP1 (0.68) CNR2CNR1KEAP1NFE2L2ALDH1A1
SCHEMBL17843319 0.78 RORC (1.00) RORCIL17A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107257788-B Benzenesulfonamide derivatives as inverse agonists of the retinoid-related orphan receptor gamma (ROR gamma (t)) 盖尔德马研究及发展公司 2020-11-10 CN disclosed
US-10457637-B2 Benzenesulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (RORγ(T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2019-10-29 US disclosed
EP-3233848-B1 BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) GALDERMA RES & DEV (FR) 2019-01-30 EP disclosed
US-20180170869-A1 BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2018-06-21 US disclosed
EP-3233848-A1 BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) Galderma Research & Development (FR) 2017-10-25 EP disclosed
WO-2016097389-A1 BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2016-06-23 WO disclosed
WO-2016097394-A1 BICYCLIC SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180170869-A1 BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) RORB, RORA, RORC RORC 3/4885CNR2 204/4885CNR1 160/4885
US-10457637-B2 Benzenesulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (RORγ(T)) RORB, RORA, RORC RORC 3/4885CNR2 188/4885CNR1 142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.